The Impact of Age-dependent Haptoglobin Deficiency on Plasma Free Hemoglobin Levels During Extracorporeal Membrane Oxygenation Support

NCT03472768 | Unknown

• 1 other identifier: 16-2058
• Study Type: observational
• Target: 90
• Locations: 1 country
• Sites: 1

Brief Summary

Newborns and children with life-threatening heart and lung failure may require support with ECMO (extracorporeal membrane oxygenation). With ECMO, oxygen and carbon dioxide are exchanged and circulated throughout the body even if the heart is unable to do so. Unfortunately, ECMO can cause breakdown of the red blood cells (known as hemolysis). For unclear reasons, newborns are at particularly high risk of hemolysis while being supported by ECMO. The amount of hemolysis is measured with concentrations of a breakdown product from red blood cells known as free hemoglobin. One possible reason for high free hemoglobin levels in newborns on ECMO could be related to another blood protein called haptoglobin. Haptoglobin is known to help in clearing free hemoglobin through the kidneys into the urine. However, haptoglobin levels in newborns can be very low and increases slowly during the first few months of life. Free hemoglobin may be inappropriately high in newborns supported by ECMO because of low levels of haptoglobin. The purpose of this study is to characterize haptoglobin, free hemoglobin, and hemolysis in newborns and children supported by ECMO and compare those values to age-matched newborns and children not on ECMO.

Conditions

Respiratory Failure

Keywords

ECMO

Outcome Measures

Primary Outcomes (2)

• Characterize the relationship between plasma haptoglobin and free hemoglobin levels in children supported by ECMO.

  Serum Haptoglobin (Hp) will be measured daily for 7 days in subjects supported by Extracorporeal Membrane Oxygenation (ECMO). In particular, the relative deficiency of Hp production in neonates will be associated with higher Hp levels. In older children with normal and adequate Hp production, there will be consistently low fHgb concentrations regardless of the other risk factors for hemolysis during ECMO support.

  Daily for 7 days

• Characterize the relationship between plasma haptoglobin and free hemoglobin levels in children supported by ECMO.

  Plasma free hemoglobin (fHgb) concentrations will be extracted from the medical record. Periods of high fHgb associated with hemolysis during ECMO support will be associated with deficiency of Hp at that time.

  7 days

Secondary Outcomes (1)

• Characterize the deficiency of plasma haptoglobin at birth.

  Daily for 3 days

Study Arms (2)

ECMO-supported group

Thirty critically-ill children (age newborn to 18 years) who are intubated and supported by ECMO. Normal adult-level haptoglobin concentrations are achieved by 6-12 months of age. We will target enrollment of 15 subjects less than 12 months of age and 15 subjects over 12 months of age

Diagnostic Test: Plasma Haptoglobin Concentration

Age-matched group with respiratory failure

Sixty critically-ill children (age newborn to 18 years) who are intubated with acute respiratory failure due to any cause and not supported by ECMO. Two control subjects will be enrolled for every 1 experimental ECMO subject.

Diagnostic Test: Plasma Haptoglobin Concentration

Interventions

Plasma Haptoglobin Concentration DIAGNOSTIC_TEST

N/A, comparison of haptoglobin concentration between groups

Age-matched group with respiratory failure; ECMO-supported group

Eligibility Criteria

• Age: Up to 18 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Critically-ill children with respiratory failure requiring mechanical circulatory and/or respiratory support.

You may qualify if:

• ECMO group - Thirty critically-ill children (age newborn to 18 years) who are intubated and supported by ECMO. We will target enrollment of 15 subjects less than 12 months of age (with at least 10 subjects enrolled less than 6 months of age) and 15 subjects over 12 months of age. These targets are set to address the secondary aim in the context of normal adult-level haptoglobin concentrations reportedly achieved by 6-12 months of age.
• Age-matched control group - Sixty critically-ill children (age newborn to 18 years) who are intubated with acute respiratory failure due to any cause and not supported by ECMO. Two control subjects will be enrolled for every 1 experimental ECMO subject. Age-matching will be performed by the following age groups:
• Neonates 37-40 weeks gestation
• Neonates 40-42 weeks gestation
• Neonates 42-44 weeks gestation
• Neonates 44-46 weeks gestation
• Neonates 46-48 weeks gestation
• Infants 2-4 months of age
• Infants 4-6 months of age
• Infants 6-12 months of age
• Children 1-4 years of age
• Children 4-8 years of age
• Children 8-12 years of age
• Children 12-18 years of age
• Age-matched control subjects will proceed through the 3 total blood sample collections even if endotracheal extubation occurs within the 3 days of study participation. Age-matching is intended to collect a sample population comparable to the ECMO subject population. We will not match to gender.

You may not qualify if:

• Personal or family history of thrombotic, hemorrhagic, or hemolytic disease.
• Personal history of hematologic malignancy.
• Premature neonates less than 37-weeks gestation and/or less than 2 kg in weight.
• Infection will not be an excluding factor for either subject group.

Sponsors & Collaborators

• University of Colorado, Denver: lead

Study Sites (1)

Children's Hospital Colorado and the University of Colorado School of Medicine

Aurora, Colorado, 80045, United States

Location

MeSH Terms

Conditions

Respiratory Insufficiency

Condition Hierarchy (Ancestors)

Respiration Disorders; Respiratory Tract Diseases

Study Officials

• John Kim, MD

  University of Colorado, Denver

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 2, 2018
• First Posted: March 21, 2018
• Study Start: September 25, 2018
• Primary Completion: September 1, 2024
• Study Completion: September 1, 2024
• Last Updated: December 13, 2023

Record last verified: 2023-12

Locations

US (1)